The FDA has fully approved Novavax's COVID-19 vaccine, but only for adults 65 and older, or those 12-64 with underlying health conditions. This contrasts with Pfizer and Moderna's vaccines, fully approved for broader use. The FDA's decision, which includes additional required trials, came after an initial target date for unrestricted approval was missed and follows skepticism expressed by some Trump administration officials. Novavax CEO John Jacobs welcomed the approval, highlighting its focus on higher-risk populations.

Prepared by Olivia Bennett and reviewed by editorial team.